Clinical AI Platform for Neurosurgery
Predicting surgical benefit.
Tracking patient recovery.
Combining functional, imaging and cognitive assessments through multimodal AI to help clinicians predict who will benefit and measure recovery.
RESEARCH & CLINICAL DEVELOPMENT
INITIAL CLINICAL PATHWAYS
Normal pressure hydrocephalus
NPH
Degenerative cervical myelopathy
DCM
THE CLINICAL NEED
Surgery is a major intervention.
Patient benefit remains uncertain.
Clinicians must decide who is likely to improve, then determine whether recovery is progressing as expected. Current assessments provide valuable information, but translating that information into reliable, individualized predictions remains challenging.
The clinical cost: operations that deliver limited improvement, missed opportunities to treat patients who could benefit, and delayed recognition of poor recovery.
THE PLATFORM
Multiple assessments.
One prediction of patient benefit.
Neurogait brings movement analysis, imaging markers and cognitive assessments into a unified patient assessment. Our goal is to turn these findings into clinically useful predictions and measurable outcomes.
FUNCTIONAL INTELLIGENCE
Turning movement into neurological insight
Neurogait uses AI to analyze gait and other movements and develop proprietary, disease-specific neurological scores, beginning with NPH and DCM.
These scores are designed to quantify functional impairment, assess treatment response and contribute to predicting surgical benefit.
INPUT
Smartphone video of patient movement
INTELLIGENCE
Proprietary neurological scores, beginning with NPH and DCM
AI-derived neurological assessment
CLINICAL PURPOSE
Surgical benefit prediction and recovery assessment
.webp)
INITIAL CLINICAL APPLICATIONS
Built around the decisions
that shape patient care.
.webp)
01 / NPH
Built for better shunt selection.
Measurable recovery.
The CSF tap test, today's standard before shunt surgery, is invasive and misses roughly 4 in 10 patients who would benefit. (systematic review, 2016) Neurogait combines its proprietary NPH score with imaging markers and cognitive assessments to help predict benefit from shunt surgery, assess response to CSF tap testing and objectively track postoperative recovery.
One multimodal AI architecture, with clinical evidence developed for each surgical pathway.
02 / DCM
Predict functional improvement.
Track postoperative recovery.
Developing proprietary neurological scores from patient movement to help predict functional benefit from decompression surgery and objectively assess postoperative recovery.
THE SURGICAL JOURNEY
Predict surgical benefit.
Measure recovery.
Our development starts with normal pressure hydrocephalus (NPH) and degenerative cervical myelopathy (DCM).
01 / BEFORE SURGERY
Who is likely to benefit?
Assess the likelihood of meaningful improvement using combined patient evidence.
02 / AFTER SURGERY
Is recovery progressing as expected?
Quantify change against the patient’s baseline and established clinical outcomes.
03 / DURING FOLLOW-UP
Who needs further assessment?
Make limited improvement or deterioration visible for clinical review.
These are development objectives. Patient selection and outcome prediction require additional clinical validation and appropriate regulatory clearance.
CLINICAL DEVELOPMENT
Validating predictions against real patient outcomes
SHEBA MEDICAL CENTER
47
participants in the initial study
Prospective proof of concept
Completed in 2023 across NPH, Parkinson’s disease and healthy controls. The early study forms a foundation for continued assessment development.
Our clinical program evaluates whether Neurogait’s assessments can identify treatment responders and consistently measure recovery.
Retrospective study · 2026
Shaare Zedek Medical Center
A secured dataset of 82 NPH patients with matched CT and longitudinal gait assessments, before and after LP and surgery. Helsinki submission underway.
Signed pilots · Execution ahead
LMU Hospital, Munich
Planned studies span NPH shunt evaluation (50 patients), DCM surgical care (50 patients), and community NPH / Parkinson’s assessment (150 participants). Approvals and execution remain ahead.
Development & regulatory status
Neurogait is under development and is not currently CE marked or FDA cleared. Clinical decisions remain with qualified healthcare professionals. Availability and intended uses will depend on validation and regulatory authorization.
OUR TEAM
The people behind Neurogait.
Clinicians, technology leaders and healthcare entrepreneurs working to improve surgical decisions and objectively measure patient recovery.
Eyal Fruchtman
CEO & Co-founder
Ben Francke
Business Development & Co-founder
Prof. Gilad Yahalom
Medical Director & Co-founder
Remi Rozycki
CTO
COMMON QUESTIONS
CLINICAL & INDUSTRY PARTNERSHIPS
Help build the evidence for
better surgical decisions.
Partner with Neurogait on clinical validation, hospital pilots or integration with neurosurgical technologies.
Patient outcomes alongside surgical technology: we are seeking partnerships with neurosurgical device and imaging companies to connect their technologies with objective patient assessment, treatment-response prediction and longitudinal outcomes.